Aortic stenosis
International guidelines now support a once-in-a-lifetime Lp(a) measurement in every adult, first phase 3 outcome trial results due in 2025 (Curr Opin Cardiol 2024)
Original title: Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?
This review by Thomas, Vedel-Krogh and Nordestgaard summarises current cardiovascular guideline recommendations on Lp(a) testing. Many international guidelines now recommend measuring Lp(a) once in a lifetime in all adults, regardless of age, sex, comorbidities or ethnicity, to aid cardiovascular risk stratification. Elevated Lp(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. Lp(a)-lowering therapy is on the horizon, with results from the first phase 3 outcome trial expected in 2025.
Original abstract
Purpose Of Review: The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity.
Recent Findings: Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025.
Summary: Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.